NKTR - Nektar Therapeutics
| Previous Close | 38.01 |
| Open | 36.71 |
| Bid | 0.00 x 3200 |
| Ask | 0.00 x 3100 |
| Day's Range | 36.23 - 38.34 |
| 52 Week Range | 33.50 - 111.36 |
| Volume | 2,870,726 |
| Avg. Volume | 2,388,410 |
| Market Cap | 6.598B |
| Beta (3Y Monthly) | 4.24 |
| PE Ratio (TTM) | 8.90 |
| EPS (TTM) | 4.28 |
| Earnings Date | Nov 5, 2018 - Nov 9, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 81.00 |
- GlobeNewswire•10 hours ago
CLASS ACTION UPDATE for JT, NKTR and AQUA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, Nov. 20, 2018 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..
- Business Wire•10 hours ago
NKTR NOTICE ALERT: Rosen Law Firm Reminds Nektar Therapeutics Investors of Important Deadline in Class Action Seeking Investor Losses – NKTR
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Nektar Therapeutics from November 11, 2017 through October 2, 2018, inclusive of the important December 31, 2018 lead plaintiff deadline in the class action.
- PR Newswire•14 hours ago
Lifshitz & Miller LLP Announces Investigation of Cognizant Technology Solutions Corp., Costco Wholesale Corporation, Datawatch Corporation, Dycom Industries, Inc., India Globalization Capital, Inc., Mercury Systems, Inc., Nektar Therapeutics, and Under Armour, Inc.
NEW YORK , Nov. 20, 2018 /PRNewswire/ -- Cognizant Technology Solutions Corp. (CTSH) Lifshitz & Miller announces investigation into possible securities laws violations in connection with allegations that ...
- Business Wire•15 hours ago
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Nektar Therapeutics To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Nektar Therapeutics (“Nektar” or the “Company”) (NKTR) of the December 31, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Nektar stock or options between November 11, 2017 and October 2, 2018 and would like to discuss your legal rights, click here: www.faruqilaw.com/NKTR. The case, Mulquin v. Nektar Therapeutics et al, No. 18-cv-06607 was filed on October 30, 2018, and has been assigned to Judge Haywood Stirling Gilliam JR.
- GlobeNewswire•yesterday
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of JT, NKTR, SYF and SONS
NEW YORK, Nov. 19, 2018 -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a.
- GlobeNewswire•yesterday
INVESTOR ALERT NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nektar Therapeutics (“Nektar” or “the Company”) (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
- GlobeNewswire•2 days ago
Kessler Topaz Meltzer & Check, LLP – Important Deadline Reminder for Nektar Therapeutics Investors
The law firm of Kessler Topaz Meltzer & Check, LLP reminds Nektar Therapeutics (Nasdaq: NKTR) (“Nektar”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of California against Nektar on behalf of purchasers of Nektar securities between November 11, 2017 through October 2, 2018, inclusive (the “Class Period”). Important Deadline Reminder: Investors who purchased Nektar securities during the Class Period may, no later than December 31, 2018, seek to be appointed as a lead plaintiff representative of the class.
Markit•2 days agoSee what the IHS Markit Score report has to say about Nektar Therapeutics.
Nektar Therapeutics NASDAQ/NGS:NKTR
- GlobeNewswire•3 days ago
SHAREHOLDER ALERT: TGTX ABBV MGTI HAS CPB CHGG ADNT GOOG NKTR SYF RBBN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, Nov. 18, 2018 -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a.
- GlobeNewswire•4 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – NKTR
NEW YORK, Nov. 16, 2018 -- Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics, Inc. (“Nektar” or the “Company”) (NASDAQ: NKTR) and.
- GlobeNewswire•5 days ago
CLASS ACTION UPDATE for TRVN, NKTR and SYF: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, Nov. 16, 2018 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..
- ACCESSWIRE•6 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – NKTR
NEW YORK, NY / ACCESSWIRE / November 14, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics, Inc. (''Nektar'' or the ''Company'') (NKTR) and certain of its officers. The class action, filed in United States District Court, Northern District of California, and index under 18-cv-06607, is on behalf of a class consisting of all persons and entities, other than Defendants and their affiliates, who purchased or otherwise acquired shares of Nektar securities between November 11, 2017 through October 2, 2018, both dates inclusive (the ''Class Period''), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the ''Exchange Act'') and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- ACCESSWIRE•6 days ago
Pawar Law Group Announces a Securities Class Action Lawsuit Against Nektar Therapeutics – NKTR
NEW YORK, NY / ACCESSWIRE / November 14, 2018 / Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Nektar Therapeutics (NASDAQ: NKTR) ...
- Motley Fool•7 days ago
Can These 2 Battered Biotech Stocks Recover?
These oncology pioneers have lost more than half their value in the past six months.
- PR Newswire•7 days ago
Nektar Appoints Wei Lin, M.D., as Senior Vice President of Clinical Development and Head of Nektar's Oncology Programs
SAN FRANCISCO, Nov. 14, 2018 /PRNewswire/ -- Nektar Therapeutics (NKTR) today announced the appointment of Wei Lin, M.D., as Senior Vice President of Clinical Development and Head of Nektar's Oncology Programs. In this role, Dr. Lin will lead development strategy and study oversight of the company's immuno-oncology candidates and other oncology programs.
- GlobeNewswire•8 days ago
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of APOG, JT, COST, CWH, OZK, NKTR and AQUA
NEW YORK, Nov. 13, 2018 -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a.
- Zacks•8 days ago
Nektar (NKTR) Catches Eye: Stock Jumps 8.7%
Nektar (NKTR) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
- ACCESSWIRE•8 days ago
Today's Research Reports on Trending Tickers: Nektar Therapeutics and Bristol-Myers Squibb
NEW YORK, NY / ACCESSWIRE / November 13, 2018 / U.S. stocks closed down on Monday as oil prices continued to slide, raising concerns amongst investors. The Dow Jones Industrial Average plunged 2.32 percent ...
- GlobeNewswire•8 days ago
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bank OZK, Nektar, and Honeywell and Encourages Investors to Contact the Firm
NEW YORK, Nov. 12, 2018 -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Bank OZK, Nektar.
- GlobeNewswire•8 days ago
SHAREHOLDER ALERT: APOG COCP ABBV COST HTHT SFIX CWH OZK NKTR SYF: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, Nov. 12, 2018 -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a.
- ACCESSWIRE•8 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – NKTR
NEW YORK, NY / ACCESSWIRE / November 12, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics, Inc. ("Nektar" or the "Company") (NKTR) and certain of its officers. The class action, filed in United States District Court, Northern District of California, and index under 18-cv-06607, is on behalf of a class consisting of all persons and entities, other than Defendants and their affiliates, who purchased or otherwise acquired shares of Nektar securities between November 11, 2017 through October 2, 2018, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- Investor's Business Daily•8 days ago
Nektar Bounds Higher On 'Promising Contender' In Cancer Immunotherapy
Nektar Therapeutics bounded higher Monday after its immunotherapy combination with Bristol-Myers Squibb showed promise as a melanoma treatment.
- ACCESSWIRE•9 days ago
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Nektar Therapeutics, Inc. (NKTR) & Lead Plaintiff Deadline: December 31, 2018
NEW YORK, NY / ACCESSWIRE / November 12, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Nektar Therapeutics, Inc. ("Nektar" or the "Company") (NKTR) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Nektar securities between November 11, 2017 through October 2, 2018, inclusive (the "Class Period"). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
- GlobeNewswire•9 days ago
Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics
The law firm of Kessler Topaz Meltzer & Check, LLP reminds that an investor securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of California against Nektar Therapeutics (Nasdaq: NKTR) (“Nektar”) on behalf of purchasers of Nektar securities between November 11, 2017 through October 2, 2018, inclusive (the “Class Period”). Nektar investors who purchased securities during the Class Period may, no later than December 31, 2018, seek to be appointed as a lead plaintiff representative of the class.
Market Realist•9 days agoMost Analysts Are Bullish on Nektar Stock
In November 2018, of the total ten analysts covering Nektar Therapeutics (NKTR), eight analysts have given the stock a “buy” or higher rating, and two analysts have given it a “hold” rating. The mean rating for Nektar Therapeutics stock is 1.8 with a target price of $88.5, implying an upside potential of 160.1% over Nektar Therapeutics’ trading price of $34.03 on November 10.
